Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023.

Autor: van Leeuwen LP; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.; Travel Clinic, Erasmus University Medical Center Rotterdam, the Netherlands.; These authors contributed equally to this work and share first authorship., Shamier MC; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.; These authors contributed equally to this work and share first authorship., Verstrepen BE; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., Götz HM; Department of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond (GGD Rotterdam-Rijnmond), Rotterdam, the Netherlands., Schmitz KS; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., Akhiyate N; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., Wijnans K; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., Bogers S; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., van Royen ME; Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands., van Gorp EC; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.; Travel Clinic, Erasmus University Medical Center Rotterdam, the Netherlands., Koopmans MP; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands., de Vries RD; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.; These authors contributed equally to this work and share senior authorship., GeurtsvanKessel CH; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.; These authors contributed equally to this work and share senior authorship., Zaeck LM; Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
Jazyk: angličtina
Zdroj: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2024 Sep; Vol. 29 (38).
DOI: 10.2807/1560-7917.ES.2024.29.38.2400575
Abstrakt: In response to the mpox outbreak in 2022 and 2023, widespread vaccination with modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as JYNNEOS or Imvanex) was initiated. Here, we demonstrate that orthopoxvirus-specific binding and MVA-neutralising antibodies waned to undetectable levels 1 year post vaccination in at-risk individuals who received two doses of MVA-BN administered subcutaneously with an interval of 4 weeks, without prior smallpox or mpox vaccination. Continuous surveillance is essential to understand the impact of declining antibody levels.
Databáze: MEDLINE